Reply  by Montalescot, Gilles
LETTERS TO THE EDITOR
Limitation of vWf
Meta-Analysis in LMWH Comparison
Differences in clinical efficacy between unfractionated heparin
(UFH) and low molecular weight heparin (LMWH) but also
between several LMWH preparations are a hot topic in research
due to differences in study results: enoxaparin proved superiority
over UFH (1,2), whereas dalteparin and nadroparin showed only
equivalence (3,4). As there is a lack of trials directly comparing
LMWHs, some investigators tried to answer the question for the
most effective LMWH preparation with data from comparative
meta-analysis: Montalescot et al. (5) published a post hoc analysis
in JACC in which they postulated differences between dalteparin
and enoxaparin concerning their action on circulating von Wille-
brand factor (vWf) levels in patients with unstable angina. This
could be of clinical importance as vWf has been shown previously
to be a predictor of outcome in acute coronary syndrome (6).
However, in scrutinizing the analytical method in Montalescot’s
work, serious drawbacks are revealed.
Montalescot et al. (5) presented a post hoc analysis that investi-
gated, in part, results from two prospective trials with enoxaparin
(1,2), one prospective trial with PEG-hirudin (PEGHIRUD 022)
and one registry with dalteparin (USIC registry). A point of criticism
is the comparison of prospective studies with a registry especially if
randomized prospective data are available (3).
In addition, the levels of vWf on UFH treatment in this
meta-analysis were obtained by pooling data from the mentioned
studies. These pooled UFH data were compared with the LMWH
results of the individual studies and the registry, respectively. This
is a questionable procedure and weakens the results. The proper
way would have been to compare the pooled UFH data with
pooled results from all cited LMWH studies.
Finally, p values were only calculated for the comparisons of
vWf levels between enoxaparin and, respectively, dalteparin and
UFH, but not directly between the LMWHs themselves, which is,
of course, impossible regarding the chosen analytical method. Only
direct comparisons (also of other surrogate markers) could provide
this data.
In our opinion, it is not correct from a scientific point of view to
draw any conclusions concerning the relative efficacy of dalteparin
and enoxaparin from these results. Although a proper post hoc
analysis can be a helpful tool in certain cases, the question for the
most effective LMWH should preferably be answered by head-to-
head studies. If these studies are not available (e.g., because of cost
reasons), the investigation of surrogate markers of hemostasis
could be feasible to predict clinical outcome and to compare
different LMWH preparations.
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REPLY
Interestingly, Dr. Ho¨dl has focused his attention only on the two
low molecular weight heparin (LMWH) treatments, whereas four
anticoagulant treatments were examined in our study. Clearly, Dr.
Ho¨dl drew more definite conclusions than we did between the two
LMWHs, because we were cautious enough not to compare
dalteparin to enoxaparin (see Fig. 1 in Ref. 1), and we only
compared each new anticoagulant treatment (enoxaparin, daltepa-
rin, PEG-hirudin) to the standard of care—unfractionated hepa-
rin (UH) (1). Also, UH was the control arm in all the randomized
studies in which our patients were included. Moreover, Dr. Ho¨dl
did not consider our warning (pg. 113 of Ref. 1) stating that “the
main limitation of our study is the lack of randomization among
the four treatment groups.”
Dr. Ho¨dl discussed post hoc analyses but forgot to mention and
to refer to the first demonstration of von Willebrand factor (vWf)
as a prognosis factor of outcome in unstable angina with a
significantly better effect of enoxaparin compared to UH in
controlling the release of vWf. These data were obtained in a
prespecified substudy of the ESSENCE trial performed in several
French centers; in a double-blind fashion, patients were random-
ized to receive either enoxaparin or UH. All clinical events were
adjudicated by the end point committee of the ESSENCE trial;
the substudy was designed and conducted prospectively, and all
samples from all centers were analyzed in a blinded fashion in a
central laboratory (2). Dr. Ho¨dl suggests using data from the
randomized FRIC trial opposing dalteparin to UH, which was
published in 1997 (3); we would be very happy to collaborate with
him on this great idea and test the vWf hypothesis in the FRIC
population. Paradoxically, Dr. Ho¨dl also states that the “proper”
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way to analyze our data would have been to pool all the data
obtained with the two different LMWHs; major chemical, bio-
logical and clinical differences exist between these LMWHs, and
there has been much debate on this issue. We believe that pooling
these data would have generated many more letters to the editor!
There are few biological markers of prognosis in unstable
angina. Our recent studies have focused attention on vWf as a new
marker of potential interest in acute coronary syndromes. It
appeared consistently as a predictive factor of outcome, and we
believe it deserves attention and further evaluation in large studies.
Our most recent publication demonstrated that the new antico-
agulants tested in unstable angina behave better than UH with
regards to vWf release. We agree it should also be confirmed.
Step-by-step we are progressing in the understanding of the role of
vWf in the prognosis of unstable angina, and the time has come for
head-to-head comparisons between the new anticoagulant treat-
ments. In that regard, the ARMADA study has now been
completed and we will share the data very soon. I am sure that Dr.
Ho¨dl will appreciate the results.
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Enoxaparin for Acute Coronary Syndromes?
Goodman et al. (1) conclude that enoxaparin is a more effective
antithrombotic treatment than unfractionated heparin (UFH) for
the prevention of rebound ischemia in patients with unstable
angina or non-Q-wave myocardial infarction. We suggest an
alternative conclusion.
Enoxaparin’s plasma half-life is two to four times longer as
compared to UFH after subcutaneous administration (2), even
more when compared to UFH given intravenously, as in the
Goodman et al. study. Activity against factor Xa and thrombin
disappears only after more than 16 h (3), following moderate doses
of enoxaparin. With high doses, as used in the ESSENCE study
(1), enoxaparin’s plasma half-life is substantially longer (4).
Therefore, after stopping study drugs in the ESSENCE study,
enoxaparin’s antithrombotic effect very likely lasted much longer
than that of UFH. After stopping UFH, ischemic events during
the 48-h monitoring period were twice as frequent as after
stopping enoxaparin (45% vs. 26%), whereas there was no differ-
ence while on active treatment (25%)—compatible with an anti-
thrombotic effect lasting about one day longer after enoxaparin. In
addition, enoxaparin’s antithrombotic effect wanes much more
slowly as compared to IV UFH. This may have added benefit by
attenuating a heparin rebound effect.
It remains to be convincingly shown whether enoxaparin or
other low-molecular-weight heparins exert superior antithrom-
botic effects as compared to UFH. Superior clinical benefit might
be explained by pharmacokinetic differences only. For patients
with acute coronary syndromes, extending the duration and slower
weaning (5) of IV UFH may well be better and cheaper.
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REPLY
Pechlaner et al. suggest that our findings (1) of less rebound
ischemia with enoxaparin as compared to unfractionated heparin
(UFH) are simply due to the longer half-life of enoxaparin.
However, the ischemic episodes (average number and duration)
identified during continuous electrocardiographic monitoring were
statistically significantly lower in the enoxaparin as compared to
the UFH group not only during the first 12 h after drug
discontinuation but also during the .12 to 24-h and even the .36
to 48-h time intervals. This suggests that the benefit seen with
enoxaparin is not simply due to prolonged half-life and greater
anti-Xa:IIa activity that “wanes” more slowly than UFH. Indeed,
there is growing evidence supporting additional mechanisms of
benefit of enoxaparin over UFH beyond the differences in phar-
macokinetics; for example, the significant blunting of the rise of
von Willebrand factor with enoxaparin in the first 48 h of
treatment (2).
As we noted, our substudy (1) was stopped at the time of overall
trial completion but prior to enrollment of an adequately powered
sample size to confidently address the initial 48-h period of active
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